Portage Biotech Inc. (PRTG)
Fuera de horario:
Portage Biotech Inc.
Clarence Thomas Building
P.O. Box 4649 Road Town
Tortola VG1110
British Virgin Islands
203 221 7378
https://www.portagebiotech.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 7
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Ian B. Walters M.B.A., M.D. | CEO & Chairman of Board | 967.65k | N/D | 1968 |
| Mr. Allan J. Lee Shaw CPA | Chief Financial Officer | 524.08k | N/D | 1964 |
| Dr. Robert A. Kramer Ph.D. | Chief Scientific Officer | 310.16k | N/D | N/D |
| Mr. Brian Wiley | Chief Business Officer | 220.69k | N/D | 1968 |
| Mr. Justin Fairchild | Vice President of Development | 283.83k | N/D | N/D |
| Mr. Joseph Ciavarella | Chief Accounting Officer | N/D | N/D | N/D |
Descripción
Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials. The company is based in Tortola, British Virgin Islands.
Gestión corporativa
La calificación ISS Governance QuickScore de Portage Biotech Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
